Madrid - A urine sample taken from three-time Tour de France winner Alberto Contador showed abnormally high levels of plastic residues that could indicate he received a transfusion of his own blood during this year's race, a person with knowledge of the test results told The Associated Press on Tuesday.
Contador, who has previously denied receiving a transfusion, was provisionally suspended by the international cycling federation last week after a small amount of the banned drug clenbuterol was discovered in one of his samples by a laboratory in Cologne, Germany.
The Spanish rider blamed contaminated beef for the result.
The Cologne lab also found plastic traces that might turn up after a transfusion of blood from a plastic bag, according to the person, who spoke to the AP on condition of anonymity because Contador's investigation by the UCI is ongoing.
Contador's abnormal sample showed eight times the normal amount of the plasticiser, the person said.
Contador has denied he underwent a blood transfusion before a gruelling mountain stage on July 22.
His spokesman, Jacinto Vidarte, on Tuesday denied any plastic residues were found in the tests.
"We are not aware of any findings of this plastic substance in any of the tests," Vidarte said. "We - officially and unofficially - have no information on anything to do with this. There were no traces of plastic in any of the tests."
Francisco Contador, the rider's brother and manager, also denied there was blood doping.
"There is not even the remotest possibility of speaking of blood manipulation because Alberto has not done anything illegal, neither in the Tour or ever," he told Cadena Ser radio on Tuesday. "We have absolutely nothing to hide."
The plasticiser test result was also reported last week by French sports daily L'Equipe and German television network ARD. The New York Times reported on the finding on Tuesday.
The person who spoke to the AP would not confirm whether the plasticiser was detected in a test on July 20 or July 21.
The UCI said the clenbuterol was detected on July 21, the Tour's final rest day. The Times quoted an anonymous source as saying the plastic residues were detected in a separate test on the previous day.
Francisco Contador said the UCI "has already stated that the July 20 doping test was negative."
UCI spokesman Enrico Carpani told the AP on Tuesday that the cycling body was continuing to work with the World Anti-Doping Agency to analyse the elements of Contador's case. He said the UCI would not comment further, citing confidentiality rules.
Contador has been provisionally suspended by the UCI and will lose his Tour de France title if he is convicted of doping. He also risks a two-year suspension.
A detection method for self-blood transfusion has yet to be fully validated, but WADA Director General David Howman told the AP last week that "its use for anti-doping purposes is partially validated and evidence from it, among others, can be used before tribunals."
Cycling and WADA officials also have the possibility of storing Contador's samples for years and retesting them once the detection method is validated.
Contador has challenged cycling authorities to freeze his urine and blood samples until technology can show he rode clean in this year's race.
Experts in blood doping say people who undergo intravenous blood transfusions for medical reasons or blood doping to increase performance are potentially exposed to the plasticiser di-(2-ethylhexyl)phthalate (DEHP) found in intravenous bags.
Experts say professional riders who cheat with blood transfusions generally receive them before big mountain stages. A French expert working for the French anti-doping agency, Professor Michel Rieu, said last month that the combined use of self-blood transfusion and micro-doses of the latest generation of blood-booster EPO is common in cycling.
A scientific study recently published by Spanish experts evaluated the exposure to DEHP by measuring the plasticizer metabolites in selected groups of subjects. It found that concentrations in urine of all three metabolites are significantly higher in people receiving blood transfusions.